샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794396

세계의 두개내 치료 전달 시장

Intracranial Therapeutic Delivery
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 272 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 두개내 치료 전달 시장은 2030년까지 33억 달러에 도달

2024년에 21억 달러로 추정되는 세계의 두개내 치료 전달 시장은 분석 기간인 2024-2030년에 CAGR 7.2%로 성장하며, 2030년에는 33억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 세포 기반 요법은 CAGR 8.2%를 기록하며, 분석 기간 종료시에는 18억 달러에 달할 것으로 예측됩니다. 유전자 치료 분야의 성장률은 분석 기간의 CAGR로 6.3%로 추정됩니다.

미국 시장은 5억 8,470만 달러로 추정, 중국은 CAGR 11.4%로 성장 예측

미국의 두개내 치료 전달 시장은 2024년에 5억 8,470만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 11.4%로 추이하며, 2030년에는 6억 8,810만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.5%와 7.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.8%로 성장할 것으로 예측됩니다.

세계의 두개내 치료 전달 시장 - 주요 동향과 촉진요인 정리

두개내 치료 전달이 신경과학의 중요한 혁신으로 부상하고 있는 이유는 무엇인가?

두개내 치료 전달은 연구자 및 임상의들이 기존의 전신 요법에 접근하기 어렵거나 반응하지 않는 복잡한 뇌 질환을 치료해야 하는 어려운 과제에 직면해 있으므로 신경과학 분야에서 빠르게 주목받고 있습니다. 중추신경계를 독소와 병원체로부터 보호하는 혈뇌장벽(BBB)은 많은 유익한 잠재적 약물이 뇌 조직 내에서 치료 농도에 도달하는 것을 막습니다. 따라서 BBB를 우회하거나 관통하는 두개내 투여 기술은 특정 뇌 부위에 치료제를 국소적으로 제어된 상태로 직접 투여할 수 있게 함으로써 신경질환 치료에 혁명을 일으키고 있습니다. 이러한 기술은 교모세포종, 파킨슨병, 간질, 알츠하이머병, 희귀 소아 신경퇴행성 질환 등의 질환 관리에 필수적입니다. 대류 촉진 전달, 척수강내 및 뇌실내 주입, 이식형 약물전달 시스템 등의 방법을 통해 임상의들은 전신 독성을 줄이면서 높은 효능을 달성할 수 있게 되었습니다. 또한 유전자 치료, 단일 클론 항체, 나노입자 등 표적 치료가 필요한 새로운 치료법의 사용도 가능해졌습니다. 전 세계에서 신경질환의 부담이 계속 증가하고 있고, 현재의 치료 접근법으로는 질병의 진행을 멈추거나 되돌릴 수 없기 때문에 두개내 치료 전달은 단순한 선택이 아닌 신경종양학, 신경퇴행학 및 기타 분야의 치료 결과를 변화시키는 데 필요한 것으로 부상하고 있습니다.

기술은 두개내 치료 기술의 정확성과 안전성을 어떻게 향상시키고 있는가?

두개내 치료 전달의 진화는 치료의 정확성, 제어 및 안전성을 크게 향상시키는 기술 발전의 물결에 의해 추진되고 있습니다. MRI 가이드 시스템이나 신경 내비게이션 플랫폼과 같은 실시간 이미징 기술은 카테터와 임플란트를 정밀하게 배치하여 건강한 뇌조직의 손상을 최소화하고 환자의 예후를 개선하고 있습니다. 바이오소재의 혁신은 뇌에 직접 지속적으로 약물을 전달할 수 있는 생분해성 고분자 및 하이드로겔의 개발로 이어졌습니다. 이러한 물질은 pH나 온도와 같은 특정 트리거에 반응하여 치료제를 방출하도록 설계할 수 있으며, 약물의 농도와 타이밍을 동적으로 제어할 수 있습니다. 미세전자기계시스템(MEMS)과 나노테크놀러지은 유량을 조절하고 생리적 신호에 반응할 수 있는 소형 펌프와 밸브를 만들 수 있게 해줍니다. 또한 연구진은 무선 제어 메커니즘을 이식형 장치에 통합하여 임상의가 환자의 반응에 따라 원격으로 투여량을 조절하고 치료법을 전환할 수 있도록 하고 있습니다. 약물유전체학 및 분자진단학의 발전도 중요한 역할을 하고 있습니다. 집속초음파 같은 기술은 혈액 뇌 장벽을 일시적으로 열어 전신 투여된 약물을 비침습적으로 표적 뇌 부위에 전달할 수 있는 것으로 연구되고 있습니다. 이러한 기술 혁신의 결과로 두개내 치료 전달은 더 효과적일 뿐만 아니라 더 안전하고 적응성이 높아져 난치성 신경질환 관리에 새로운 가능성을 제시하고 있습니다.

질병의 복잡성과 환자의 고유한 요구가 두개내 투여 전략을 어떻게 형성하는가?

두개내 치료 전달 전략은 신경질환의 유형과 부위, 진행 단계, 각 환자의 고유한 해부학적, 생리적 특징에 따라 크게 영향을 받습니다. 고악성 신경교종이나 뇌전이와 같이 종양이 주변 조직에 침범하여 전신 화학요법에 저항성을 보이는 경우, 세포독성 약물이나 면역치료제를 종양층에 직접 주입함으로써 전신적인 부작용이 적고 보다 표적화된 접근이 가능해집니다. 파킨슨병과 같은 신경퇴행성 질환은 흑질이나 기저핵과 같은 뇌 깊숙한 곳까지 투여가 필요하며, 높은 공간적 정확도와 만성 투여 능력이 요구됩니다. 라이소좀 저장 장애나 백질 이영양증 소아 환자의 경우, 바이러스 벡터를 이용하여 뇌척수액이나 뇌실에 투여하는 두개내 유전자 치료를 통해 근본적인 유전적 결함을 장기적으로 개선할 수 있는 가능성이 있습니다. 각 질환은 투여 경로, 제제의 안정성, 투여 스케줄 등의 측면에서 고유한 과제를 안고 있습니다. 또한 나이, 과거 수술력, 면역반응, 동반질환 등의 환자 요인도 두개내 투여 프로토콜의 설계와 시행에 영향을 미칩니다. 현재 병원과 연구센터에서는 신경외과 전문의, 신경과 전문의, 영상의학과 전문의, 약리학자 등으로 구성된 다학제적 팀을 활용하여 치료 효과를 최적화하는 동시에 치료 위험을 최소화하는 치료 계획을 수립하고 있습니다. 또한 국소 병변과 미만성 병변을 모두 표적으로 삼기 위해 두개내 투여와 전신 투여를 결합한 하이브리드 접근법에 대한 관심도 높아지고 있습니다. 정밀의학이 계속 확산되고 있는 가운데, 두개내 치료 전달의 개별화 능력은 치료 결과의 향상과 첨단 신경치료제의 보급에 필수적입니다.

전 세계 두개내 치료 전달 시장의 성장을 가속하는 요인은 무엇인가?

두개내 치료 전달 시장의 성장은 질병 부담, 기술력, 규제 지원, 진화하는 치료 패러다임과 관련된 여러 가지 교차하는 추세에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 신경질환, 특히 알츠하이머병, 파킨슨병, 뇌졸중과 같은 질환이 증가하고 있는 고령화 사회에서 전 세계에서 발병률이 증가하고 있다는 점입니다. 이러한 질환에 대한 기존 치료법의 효과가 제한적이기 때문에 BBB와 질환의 불균일성 등의 장벽을 극복할 수 있는 표적화된 국소 치료제에 대한 투자가 확대되고 있습니다. 뇌에 직접 투여해야 하는 생물제제, 유전자 치료제, 세포 기반 치료제의 파이프라인이 확대되고 있는 것도 혁신적인 전달 플랫폼에 대한 수요를 증가시키고 있습니다. 규제 당국은 새로운 신경학 치료법을 개발하는 기업에게 패스트트랙 및 희귀질환 치료제 지정을 통해 두개내 전달 기술의 개발 및 승인을 가속화하고 있습니다. 민관으로부터 많은 자금 지원을 받아 희귀질환과 일반 중추신경계 질환에 대한 두개내 전달의 활용을 모색하는 임상시험이 지원되고 있습니다. 한편, 이미징, 내비게이션, 바이오소재의 기술 발전은 시술의 위험을 줄이고 의사들의 신뢰도를 높이고 있습니다. 학술연구센터, 생명공학 기업, 의료기기 제조업체 간의 협력 강화는 진단, 전달, 치료 모니터링을 단일 플랫폼에 통합하는 통합 솔루션으로 이어지고 있습니다. 또한 환자 옹호 단체와 신경학 재단이 조기 진단과 보다 적극적인 치료 접근법을 장려하기 위해 인지도를 높이고 있으며, 병변 부위에 직접 개입할 수 있는 치료법에 대한 수요를 창출하고 있습니다. 이러한 힘들이 결합되어 두개내 치료 전달의 세계 보급이 가속화되고 있으며, 미래 신경과학 혁신의 초석으로 자리매김하고 있습니다.

부문

치료법(세포 기반 치료, 유전자 치료, 효소 보충 요법), 적응증(척수성 근위축증 적응증, 다발성 경화증 적응증, 바텐병 적응증, 근위축성측색경화증 적응증)

조사 대상 기업의 예

  • Abyrx, Inc.
  • Alcyone Therapeutics
  • Antisense Therapeutics Ltd
  • B. Braun Melsungen AG
  • Biogen Inc.
  • Brainlab AG
  • Cala Health, Inc.
  • Cerebrum Tech
  • Codman Neuro(Integra LifeSciences)
  • Elekta AB
  • Flowonix Medical Inc.
  • Insightec Ltd.
  • Medtronic plc
  • NeuroSigma, Inc.
  • Neurotech Pharmaceuticals, Inc.
  • NXDC, Inc.(Neuralink competitor)
  • Roche Holding AG
  • Renishaw plc
  • Synchron, Inc.
  • VeriTouch Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Intracranial Therapeutic Delivery Market to Reach US$3.3 Billion by 2030

The global market for Intracranial Therapeutic Delivery estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Cell-based Therapy, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Gene Therapy segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$584.7 Million While China is Forecast to Grow at 11.4% CAGR

The Intracranial Therapeutic Delivery market in the U.S. is estimated at US$584.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$688.1 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Intracranial Therapeutic Delivery Market - Key Trends & Drivers Summarized

Why Is Intracranial Therapeutic Delivery Emerging as a Critical Innovation in Neuroscience?

Intracranial therapeutic delivery is rapidly gaining prominence in the field of neuroscience as researchers and clinicians confront the formidable challenge of treating complex brain disorders that are often inaccessible or unresponsive to conventional systemic therapies. The blood-brain barrier (BBB), which protects the central nervous system from toxins and pathogens, also prevents many potentially beneficial drugs from reaching therapeutic concentrations in brain tissue. Intracranial delivery techniques, which bypass or penetrate the BBB, are therefore revolutionizing the treatment of neurological conditions by allowing for localized, controlled, and direct administration of therapeutic agents to specific brain regions. These techniques are critical in managing diseases such as glioblastoma, Parkinson’s disease, epilepsy, Alzheimer’s, and rare pediatric neurodegenerative disorders. Methods such as convection-enhanced delivery, intrathecal and intraventricular infusions, and implantable drug delivery systems are enabling clinicians to achieve higher efficacy with lower systemic toxicity. They also permit the use of novel treatment modalities like gene therapy, monoclonal antibodies, and nanoparticles that require targeted delivery to be effective. As the burden of neurological diseases continues to rise globally and current treatment approaches fall short in halting or reversing disease progression, intracranial therapeutic delivery is emerging not just as an option but as a necessity for transforming outcomes in neuro-oncology, neurodegeneration, and beyond.

How Is Technology Enhancing the Precision and Safety of Intracranial Therapeutic Techniques?

The evolution of intracranial therapeutic delivery is being propelled by a wave of technological advancements that are significantly improving the precision, control, and safety of treatment. Real-time imaging technologies such as MRI-guided systems and neuronavigation platforms allow for highly accurate placement of catheters and implants, minimizing damage to healthy brain tissue and improving patient outcomes. Innovations in biomaterials have led to the development of biodegradable polymers and hydrogels that can deliver drugs over sustained periods directly within the brain. These materials can be engineered to release therapeutic agents in response to specific triggers like pH or temperature, offering dynamic control over drug concentration and timing. Microelectromechanical systems (MEMS) and nanotechnology are enabling the creation of miniaturized pumps and valves that can modulate flow rates and respond to physiological signals. Additionally, researchers are integrating wireless control mechanisms into implantable devices, allowing clinicians to remotely adjust dosing or switch therapies based on patient response. Advances in pharmacogenomics and molecular diagnostics are also playing a key role, as they help personalize therapy by aligning drug choice and delivery methods with the patient’s genetic and molecular profile. Techniques such as focused ultrasound are being studied for their potential to temporarily open the blood-brain barrier, allowing noninvasive delivery of systemically administered drugs to targeted brain areas. Collectively, these innovations are making intracranial therapeutic delivery not only more effective but also safer and more adaptable, opening new possibilities in the management of previously intractable neurological conditions.

How Do Disease Complexity and Patient-Specific Needs Shape Intracranial Delivery Strategies?

Intracranial therapeutic delivery strategies are heavily influenced by the type and location of the neurological disease, its stage of progression, and the unique anatomical and physiological characteristics of each patient. In cases such as high-grade gliomas or brain metastases, where tumors infiltrate surrounding tissue and are resistant to systemic chemotherapy, direct infusion of cytotoxic agents or immunotherapeutics into the tumor bed provides a more targeted approach with fewer systemic side effects. Neurodegenerative conditions like Parkinson’s disease require delivery to deep brain structures such as the substantia nigra or basal ganglia, necessitating high spatial accuracy and chronic administration capabilities. In pediatric patients with lysosomal storage disorders or leukodystrophies, intracranial gene therapy administered via viral vectors into the cerebrospinal fluid or brain ventricles offers the potential for long-term correction of underlying genetic defects. Each condition poses unique challenges in terms of delivery route, formulation stability, and dosing schedule. Furthermore, patient factors such as age, previous surgeries, immune response, and coexisting medical conditions also shape the design and implementation of intracranial delivery protocols. Hospitals and research centers are now leveraging multidisciplinary teams of neurosurgeons, neurologists, radiologists, and pharmacologists to tailor treatment plans that optimize therapeutic efficacy while minimizing procedural risks. There is also growing interest in hybrid approaches that combine intracranial and systemic delivery to target both localized lesions and diffuse pathology. As precision medicine continues to gain traction, the ability to individualize intracranial therapeutic delivery will be crucial in improving treatment outcomes and expanding the reach of advanced neurotherapeutics.

What Factors Are Driving the Global Expansion of the Intracranial Therapeutic Delivery Market?

The growth in the intracranial therapeutic delivery market is driven by several intersecting trends related to disease burden, technological capability, regulatory support, and evolving treatment paradigms. One of the major drivers is the increasing global incidence of neurological disorders, particularly in aging populations, where conditions such as Alzheimer’s, Parkinson’s, and stroke are on the rise. The limited efficacy of existing treatment modalities for these conditions is prompting greater investment in targeted, localized therapies that can overcome barriers like the BBB and disease heterogeneity. The expanding pipeline of biologics, gene therapies, and cell-based treatments that require direct brain administration is also boosting demand for innovative delivery platforms. Regulatory agencies are providing fast-track and orphan drug designations to companies developing novel neurological therapies, accelerating the development and approval of intracranial delivery technologies. Significant funding from public and private sources is supporting clinical trials that explore the use of intracranial delivery for both rare and common CNS diseases. Meanwhile, technological advancements in imaging, navigation, and biomaterials are reducing procedural risk and enhancing physician confidence in these techniques. Increasing collaboration between academic research centers, biotech firms, and medical device manufacturers is leading to integrated solutions that combine diagnostics, delivery, and therapeutic monitoring into a single platform. Furthermore, patient advocacy groups and neurological foundations are raising awareness and pushing for earlier diagnosis and more aggressive treatment approaches, creating demand for therapies that can intervene directly at the site of pathology. These combined forces are accelerating the global adoption of intracranial therapeutic delivery and positioning it as a cornerstone of future neuroscience innovation.

SCOPE OF STUDY:

The report analyzes the Intracranial Therapeutic Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Cell-based Therapy, Gene Therapy, Enzyme Replacement Therapy); Indication (Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication, Amyotrophic Lateral Sclerosis Indication)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abyrx, Inc.
  • Alcyone Therapeutics
  • Antisense Therapeutics Ltd
  • B. Braun Melsungen AG
  • Biogen Inc.
  • Brainlab AG
  • Cala Health, Inc.
  • Cerebrum Tech
  • Codman Neuro (Integra LifeSciences)
  • Elekta AB
  • Flowonix Medical Inc.
  • Insightec Ltd.
  • Medtronic plc
  • NeuroSigma, Inc.
  • Neurotech Pharmaceuticals, Inc.
  • NXDC, Inc. (Neuralink competitor)
  • Roche Holding AG
  • Renishaw plc
  • Synchron, Inc.
  • VeriTouch Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Intracranial Therapeutic Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Brain Tumors and Neurological Disorders Throws the Spotlight on Intracranial Therapeutic Delivery as a Frontier in Precision Medicine
    • Limitations of Systemic Therapies Propel Demand for Direct-to-Brain Delivery Methods That Bypass the Blood-Brain Barrier
    • Here's the Story: Advances in Drug Delivery Technologies Strengthen the Business Case for Intracranial Approaches in Refractory CNS Conditions
    • Growth in Targeted Neuro-Oncology Treatments Drives Use of Convection-Enhanced Delivery (CED) and Intraventricular Infusion Techniques
    • Here's How Image-Guided and Robotic-Assisted Systems Are Enabling Greater Accuracy and Safety in Intracranial Administration
    • Expansion of Gene and Cell Therapy Pipelines Fuels Need for Controlled, Localized Delivery Within the Central Nervous System
    • Rising Focus on Pediatric and Rare Neurological Disorders Supports Innovation in Minimally Invasive Delivery Platforms
    • Here's How Biodegradable Implants and Depot Formulations Are Improving Drug Retention and Reducing Invasive Re-Intervention
    • Here's How MRI-Compatible and Real-Time Monitoring Technologies Are Enhancing Intracranial Delivery Precision
    • Patient-Centric Design and Hospital Workflow Integration Become Critical for Adoption in Specialized Neurosurgical Settings
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Intracranial Therapeutic Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Intracranial Therapeutic Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Intracranial Therapeutic Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cell-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cell-based Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Cell-based Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Spinal Muscular Atrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Spinal Muscular Atrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Spinal Muscular Atrophy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Batten Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Batten Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Batten Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Amyotrophic Lateral Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Amyotrophic Lateral Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Amyotrophic Lateral Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • JAPAN
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • CHINA
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • EUROPE
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Intracranial Therapeutic Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Intracranial Therapeutic Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • FRANCE
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • GERMANY
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Intracranial Therapeutic Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Intracranial Therapeutic Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • INDIA
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Intracranial Therapeutic Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Intracranial Therapeutic Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Intracranial Therapeutic Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Intracranial Therapeutic Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030
  • AFRICA
    • Intracranial Therapeutic Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Intracranial Therapeutic Delivery by Therapy - Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Intracranial Therapeutic Delivery by Therapy - Percentage Breakdown of Value Sales for Cell-based Therapy, Gene Therapy and Enzyme Replacement Therapy for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Intracranial Therapeutic Delivery by Indication - Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Intracranial Therapeutic Delivery by Indication - Percentage Breakdown of Value Sales for Spinal Muscular Atrophy Indication, Multiple Sclerosis Indication, Batten Disease Indication and Amyotrophic Lateral Sclerosis Indication for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제